Nyxoah Sa ( (NYXH) ) has released its Q3 earnings. Here is a breakdown of the information Nyxoah Sa presented to its investors.
Nyxoah SA is a Belgian medical technology company specializing in innovative solutions for treating Obstructive Sleep Apnea (OSA) with its Genio® system, a minimally invasive neurostimulation therapy. The company’s recent earnings report highlights a significant increase in revenue, reaching €3.3 million for the first nine months of 2024, primarily driven by its European market presence, especially in Germany. Key clinical advancements include the successful completion of the DREAM IDE trial, meeting primary endpoints for safety and efficacy, and ongoing efforts to expand its market reach in the U.S. and Europe. Nyxoah reported a net loss of €42.1 million, attributed to increased operating expenses, but strengthened its cash position to €71 million through funding activities. Looking ahead, Nyxoah plans to continue its commercialization efforts in Europe and anticipates potential FDA approval to advance its U.S. market entry, focusing on regulatory and market access strategies.
